Fibrilación auricular y flúter auricular

  1. Gómez, M. Valverde
  2. Granero, C. Lozano
  3. Muñoz, D. Rodríguez
  4. Gómez, J.L. Zamorano
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2017

Título do exemplar: Enfermedades cardiológicas (V) Arritmias (II)

Serie: 12

Número: 39

Páxinas: 2299-2308

Tipo: Artigo

DOI: 10.1016/J.MED.2017.07.010 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Obxectivos de Desenvolvemento Sustentable

Resumo

Abstract/Introduction Atrial fibrillation is the most frequent sustained arrhythmia, with a prevalence of 3% in the general population, although with a higher prevalence in the elderly, hypertensive, obese and patients with structural heart disease. Diagnosis The electrocardiographic diagnosis is based on the identification of the irregularly irregular pattern R-R characteristic. As part of the study, it is convenient to perform a transthoracic echocardiogram, which allows us to diagnose the presence of structural heart disease and to assess the atrial size, which is important for an ablation procedure, and a complete analysis with a thyroid profile, in order to rule out Other triggers, such as anemia, infection, or hyperthyroidism. Management The management of this pathology is based on three pillars: antithrombotic therapy for the prevention of systemic embolism and cerebrovascular accidents, current in recent years thanks to the appearance of oral alternatives to classical anticoagulant therapy with vitamin antagonists K; Heart rate control with braking agents, especially beta-adrenergic blockers, but also calcium-antagonists and digoxin; And rhythm control strategies, both pharmacological and percutaneous, the latter increasingly widespread due to its greater effectiveness and low incidence of complications.

Referencias bibliográficas

  • Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: A population-based study. Stroke. 2013;44(11):3103-8.
  • Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129(8):837-47.
  • Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-20.
  • Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS. Lifetime risk for development of atrial fibrillation: The framingham heart study. Circulation. 2004;110(9):1042-6.
  • Stewart S, Hart CL, Hole DJ, Mcmurray JJ V. a population-based study of the long term risks associated with atrial fibrillation : 20-year followup of the Renfrew/Paisley Study. Am J Med. 2002;113:359-364.
  • Andersson T, Magnuson A, Bryngelsson IL, Frøbert O, Henriksson KM, Edvardsson N. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995-2008: A Swedish nationwide long-term case-control study. Eur Heart J. 2013;34(14):1061-7.
  • García Cosío F, Pastor A, Núñez A, Magalhaes AP, Awamleh P. Flúter auricular: perspectiva clínica actual. Rev Española Cardiol. 2006;59(8):816-31.
  • Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180-4.
  • Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129(2):145-56.
  • Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230-46.
  • Benussi S. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. En prensa 2017.
  • Fontenia Cerezuela A, López Gil M, Salguero Bodes R, Arribas Ynsaurriaga F. Flúter auricular y otras taquiarritmias auriculares macro reentrantes. Manual de arritmias y electrofisiología cardíaca. Barcelona: Pulso Ediciones; 2010. p. 232-49.
  • Benjamin EJ, Wolf PA, Agostino RBD, Silbershatz H, Kannel WB, Levy D. Clinical investigation and reports impact of atrial fibrillation on the risk of death The Framingham Heart Study. Circulation. 1998;98(10):946-53.
  • Manuscript A, Nanostructures SPC. NIH Public Access. Nano. 2008; 6(9):2166-71.
  • Wynn GJ, Todd DM, Webber M. The European Heart Rhythm Association symptom classification for atrial fibrillation: Validation and improvement through a simple modification. Europace. 2014;16(7):965-72.
  • Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY. Safety and efficacy of digoxin: systematic review and meta-analysis of observa-tional and controlled trial data. BMJ. 2015;351:h4451.
  • Kotecha D, Piccini JP. Atrial fibrillation in heart failure: What should we do? Eur Heart J. 2015;36(46):3250-7.
  • Manolis AJ, Rosei EA, Coca A. Hypertension and atrial fibrillation. J Hypertens. 2012;30(2):239-52.
  • Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW. Atrial fibrillation management: A prospective survey in ESC Member Countries - The Euro Heart Survey on atrial fibrillation. Eur Heart J. 2005;26(22):2422-34.
  • De Caterina R, Camm AJ. What is “valvular” atrial fibrillation? A reappraisal. Eur Heart J. 2014;35(47):3328-35.
  • Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation. Jama. 2013;310(19):2050.
  • Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-72.
  • Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH. A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest. 2010;138(5):1093-100.
  • Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation 2.3 year followup of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation. 2013;127(6):720-9.
  • Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W. Updated European Heart Rhythm Association Practical Guide on the use of non Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507.
  • Groenveld HF, Crijns HJGM, Van Den Berg MP, Van Sonderen E, Alings AM, Tijssen JG. The effect of rate control on quality of life in patients with permanent atrial fibrillation: Data from the race II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011;58(17):1795-803.
  • Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J. 2009; 85(1004):303-12.
  • Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660-8.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-200.
  • Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am Heart J. 2006;151(4):2-7.
  • Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol. 1998;81(12): 1450-4.
Fonte de datos: Dialnet